(24/7 MARKET NEWS) – The Board of Directors of Jounce Therapeutics, Inc. (NASDAQ: JNCE) reported receiving an unsolicited and non-binding proposal to acquire 100% of the equity of Jounce from Concentra Biosciences, LLC, currently an approximately 10.2% shareholder of Jounce, for $1.80 in cash per share plus a contingent value right (“CVR”) representing the right to receive 80% of the net proceeds payable from any license or disposition of certain of Jounce’s legacy programs.
Jounce Therapeutics is trading at $1.44, up $0.38 (+35.85%), on 4.8 million premarket shares.
Its 52-week trading range is $0.5773 to $7.94. It’s now trading above its recent resistance levels and if it maintains today’s strong trading volume, its setup is favorable to potential retrace November’s move to $2+.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
